22 results about "Plasma Exchanges" patented technology

The present invention provides a method of removing microplastics from blood or body of a subject, including one or more tissues of the subject, by extracorporeal blood purification, including by plasma exchange, such as double filtration plasma exchange. The present invention also provides a method of treating medical conditions and methods of improving healthy lifespan and lifespan using extracorporeal blood purification, including plasma exchange, such as double filtration plasma exchange, such as by filtering microplastics from blood, and removing microplastics from a tissue or body of a subject, such as a human subject.

The invention provides a method and a device for secondary filtration and re-removal of cholesterol ester after continuous blood purification and blood fat filtration, and belongs to the technical field of medical blood purification. According to the method and the device, the technology of combining enzymolysis, adsorption and membrane separation is adopted for residual CE in a CBP filtering product. The method comprises the following steps: firstly, decomposing CE into small molecules by using specific enzyme, and weakening the combination of CE and other components; residual impurities are further adsorbed through a high-performance adsorption material; and finally, efficient removal of CE is realized by virtue of a high-precision membrane separation technology, so that the residual quantity is reduced to be below a safety threshold value. Compared with a traditional technology, the problems that the CE-containing filtrate is high in recycling risk and low in resource utilization rate are effectively solved, the purity of a filtered product is remarkably improved, technical support is provided for industrial scenes such as plasma exchange, filtrate feedback, biopharmacy and extracorporeal circulation in the medical field, and the application prospect is wide. The safety and the resource utilization efficiency of the blood purification technology are promoted.

An optimizing device for freely switching RBC removal and plasma exchange are provided, which is used to solve the problems in the prior art that the treatment effect is poor, the consumption of consumables is excessive, and the application range is narrow. According to the device, an additional hanging hook is added, a plasma exchange output pipeline is modified to be separated from the plasma collection pump and to be installed to the additional hanging hook. Then, the RBC recirculation tube is clamped through a freely movable cassette, so that the flow rate control of a plasma collection pump is released. Thereafter, HCT data is adjusted, and liquid is compensated, so that the RBC removal or replacement, lymphoplasma exchange and plasma exchange can be freely switched, which can meet the clinical treatment needs, optimize the process and reduce the cost. Therefore, the application range of a pipeline is greatly increased.

The present disclosure relates to the treatment of cognitive disorders, such as senescence-related cognitive impairment. In certain aspects, the disclosure describes methods of detecting one or more than one protein selected from the group consisting of DLL1, VNN2, VAV3, and SUMF1 from a sample obtained from a subject suffering from or suspected of suffering from a cognitive impairment. In certain embodiments, the cognitive impairment is caused by a degenerative disease of the nervous system, such as Alzheimer's disease. The method further includes identifying the subject as being likely or not likely to respond positively to plasma exchange therapy. In even other aspects, the present disclosure describes methods for treating cognitive impairment in a subject by plasma exchange therapy in which the subject is identified as likely or impossible to respond positively to the plasma exchange therapy based on particular protein expression data. The plasma exchange therapy may be full volume plasma exchange and / or low volume plasma exchange. Kits suitable for implementing the methods disclosed herein are also provided.

The utility model discloses equal ion exchange equipment for water purification treatment, which comprises an equal ion exchange equipment body, the surface of the equal ion exchange equipment body is fixedly sleeved with a connecting ring, the left side of the connecting ring is fixedly connected with a shell, the top of the shell is provided with a circular groove, and the input end of the equal ion exchange equipment body is communicated with a connecting pipe. The input end of the connecting pipe communicates with the output end of the shell, the input end of the shell communicates with an input pipe, and a filtering mechanism is arranged in the shell. The utility model has the advantage of improving the exchange efficiency, and solves the problems that the resin performance is gradually reduced and the ion exchange efficiency is directly reduced due to the reduction of the resin performance because a large number of impurities are usually contained in water and have adverse effects on the resin in the equipment along with the long-time operation of the equipment. And the maintenance cost of the equipment is greatly increased.

The plasma exchange auxiliary device comprises a water bath box, a heating wire is arranged in the water bath box, a cover plate is arranged at the top of the water bath box, a through groove is formed in the upper surface of the water bath box, a motor is installed on the upper surface of the cover plate, a threaded rod is installed at the output end of the motor, and a threaded rod is installed at the output end of the threaded rod. And the outer surface of the threaded rod is in threaded connection with a moving plate, the bottom end of the moving plate penetrates through the through groove and is fixedly connected with a hanging plate, and a set of first fixing clamps are installed on the bottom face of the hanging plate. Through cooperation of the cover plate, the through groove, the motor, the threaded rod, the moving plate, the hanging plate, the first fixing clamp, the bottom plate and the second fixing clamp, the plasma bag can be stably clamped through the first fixing clamp and the second fixing clamp, meanwhile, the motor is controlled to work in a reciprocating mode, the hanging plate can drive the first fixing clamp to move in a reciprocating mode, and the top of the plasma bag can swing back and forth; and the plasma flows in the plasma bag, so that the plasma can be uniformly heated, and the treatment effect of the plasma is further ensured.

The invention relates to the technical field of medicines, and particularly discloses application of ipropam in preparation of a medicine for treating immune thrombocytopenic purpura. Aiming at the clinical problem that the condition of a patient with refractory recurrent immune thrombotic thrombocytopenic purpura (iTTP) still progresses after the treatment of plasma exchange combined with hormone, repatumab and immune globulin is invalid, the complement abnormal activation marker of the patient is detected to be increased, which indicates that the complement bypass way participates in disease recurrence refractory; ipropam is combined with plasma exchange, hormone and rituximab for treatment. Results show that the hemoglobin and platelet count is significantly increased after treatment for 5 days, mental symptoms are improved in 9 days, creatinine returns to normal in 11 days, ADAMTS13 activity is less than 0.2 IU / dL in 14 days, an inhibitor turns negative, and ADAMTS13 activity, hemoglobin and platelet return to normal in the fifth week. According to the application, it is proved for the first time that ipropam can effectively reverse the pathological process of refractory iTTP by inhibiting complement bypass pathway activation, and a new treatment strategy is provided for the disease.

The application discloses a plasma replacement device based on pipeline pressure intelligent monitoring and belongs to the technical field of medical instruments. The plasma replacement device based on pipeline pressure intelligent monitoring comprises a side support plate, a clamping block is arranged on the inner side of the side support plate, an extraction pipeline and an input pipeline are respectively arranged on the clamping block, an extrusion assembly is arranged in the middle of the extraction pipeline and the input pipeline, the extraction pipeline is connected with a centrifugal assembly, and the input pipeline is connected with a replacement assembly. The application solves the problem that the prior art cannot detect the pressure of the pipeline, thereby causing the pipeline to leak or the blood flow to be abnormal and the problem that the abnormality cannot be found in time, the application can automatically identify the pipeline leakage or blood flow abnormality risk and timely adjust, the pipeline leakage and blood flow abnormality in the process of plasma replacement cannot be found in time, thereby causing damage to the health of the patient, the monitoring data is consistent with the actual physiological state, and the medical effect of plasma replacement is improved.

The present disclosure provides methods of using zilucoplan as a therapy for AChR positive gMG patients who have gMG refractory to conventional immunosuppressive therapy and / or intravenous (IV) immunoglobulin and plasma exchange (PLEX) therapy.

The utility model discloses an improved centrifugal separator DPMAS combined plasma exchange device. An improved centrifugal separator DPMAS combined plasma exchange device comprises a blood drawing pipe connected with the artery of the human body, the front end of the blood drawing pipe is connected with a plasma separator, and the output end of the bottom of the plasma separator is connected with a blood return pipe capable of being connected with the vein of the human body. The output end of the side face of the plasma separator is connected with an adsorption filtration pipeline through a plasma input pipe, the output end of the adsorption filtration pipeline is connected with a blood return pipe through a plasma output pipe, and a plasma input pump is arranged on the plasma input pipe. A liquid discharge pipeline is connected to the plasma input pipe between the plasma input pump and the adsorption filtration pipeline through a liquid discharge three-way pipe, and a replacement pipeline is connected to the plasma output pipe close to the blood return pipe through a replacement three-way pipe. According to the utility model, the DPMAS mode and the plasma exchange mode can be conveniently switched, the operation steps can be simplified, and the infection risk of a patient can be reduced.

Methods and materials for reducing the level of circulating extracellular mesothelin (also referred to herein as soluble MSLN or sMSLN) by therapeutic plasma exchange (TPE) are provided herein. For example, methods and materials for using TPE to reduce the level of sMSLN in mammals (e.g., humans) identified as having mesothelioma or another solid tumor are provided herein.

An optimizing device for freely switching RBC removal and plasma exchange are provided, which is used to solve the problems in the prior art that the treatment effect is poor, the consumption of consumables is excessive, and the application range is narrow. According to the device, an additional hanging hook is added, a plasma exchange output pipeline is modified to be separated from the plasma collection pump and to be installed to the additional hanging hook. Then, the RBC recirculation tube is clamped through a freely movable cassette, so that the flow rate control of a plasma collection pump is released. Thereafter, HCT data is adjusted, and liquid is compensated, so that the RBC removal or replacement, lymphoplasma exchange and plasma exchange can be freely switched, which can meet the clinical treatment needs, optimize the process and reduce the cost. Therefore, the application range of a pipeline is greatly increased.

Disclosed herein are human blood fractions depleted of disease-causing extracellular vesicles, prepared by plasma exchange, that may find use in the treatment of a cancer. In particular, the depleted blood fractions may find use in treating KRAS mutant cancers.

The invention relates to the technical field of medical separation equipment, and particularly discloses an efficient plasma exchange type blood routine condensation collection treatment device which comprises a machine body and a fixing plate, an extraction assembly is arranged on the outer side of the fixing plate, and the extraction assembly comprises a piston cylinder connected with the outer surface of the fixing plate in a clamped mode; a piston plate is slidably connected to the inner surface of the piston cylinder, a piston rod is fixedly connected to the outer surface of the upper end of the piston plate, a contact block is fixedly connected to the upper end of the piston rod, and a mounting sleeve is fixedly connected to the middle of the outer surface of the fixing plate. By arranging the extraction assembly, plasma in the test tube is sucked into the liquid suction tube under the action of gas pressure, so that the plasma can be separated from a cell layer, plasma separation and replacement treatment can be performed on multiple groups of blood samples at the same time, and the condensation and collection treatment speed of conventional blood samples can be effectively increased; and the sample treatment efficiency can be remarkably improved while the sample treatment precision is ensured.

The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and / or low volume plasma exchange. Also provided are kits suitable for performing such methods.

1. Name of the product in this design: Blood purification equipment. 2. Application of this design: for patients undergoing continuous blood purification therapy, plasma exchange therapy, plasma adsorption therapy, albumin adsorption therapy, hemoperfusion therapy, and extracorporeal carbon dioxide removal therapy. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. Other situations requiring explanation: Part A is made of transparent material.

The present disclosure provides methods of using zilucoplan as a therapy for AChR positive gMG patients non-refractory to conventional immunosuppressive therapy and / or intravenous (IV) immunoglobulin and plasma exchange (PLEX) therapy.

The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and / or low volume plasma exchange. Also provided are kits suitable for performing such methods.

Disclosed herein are human blood fractions depleted of disease-causing extracellular vesicles, prepared by plasma exchange, that may find use in the treatment of a condition selected from the group consisting of neurodegenerative disease, autoimmune disease, cardiovascular disease, renal disease, and liver disease. In particular, the depleted blood fractions may find use in treating neurodegenerative diseases such as Parkinson's Disease or Alzheimer's Disease.

The utility model provides a special connecting pipeline for double plasma exchange treatment, which is used for connecting a plasma component separator and a plasma separator, and comprises an artery tube, a vein tube, a waste liquid tube, a return tube, a plasma tube, a pressure measuring tube and a waste liquid bag, one end of the artery tube and one end of the vein tube are respectively connected to two ends of the plasma separator, and the other end of the artery tube and the other end of the vein tube are respectively connected to the other end of the plasma separator; a side port of the plasma separator is connected with the plasma tube, the other end of the plasma tube is fixedly connected with the end of the plasma component separator, the other end of the plasma component separator is fixedly connected with the waste liquid tube, and the other end of the waste liquid tube is fixedly connected with the waste liquid bag. A side port of the plasma component separator is fixedly connected with a return pipe, the other end of the return pipe is communicated with an arterial duct, and a pressure measuring pipe is arranged on the arterial duct in a communicated mode. The connecting pipe does not need to be installed repeatedly, consumables are saved, use is convenient, and sterile operation is guaranteed.

The present invention relates to a composition comprising albumin for use in the treatment of Amyotrophic Lateral Sclerosis (ALS), wherein the composition is administrated to the patient by plasma exchange using a volume of said composition equivalent to approximately 100 % of the volume of plasma withdrawn from the patient, and with a frequency of twice a week the first 3 weeks and once a week for the following 21 weeks, for a total period of 24 weeks.

The invention relates to the technical field of bioengineering, in particular to a biomarker for evaluating the prognosis condition of a liver injury patient subjected to plasma exchange treatment and application of the biomarker. The biomarker comprises circulating mitochondrial DNA (deoxyribonucleic acid). Circulating mitochondrial DNA is used as a biomarker for evaluating the prognosis condition of the liver injury patient subjected to plasma exchange treatment, so that the prognosis early warning function of the liver injury patient subjected to plasma exchange can be realized, the survival rate of the patient is remarkably improved, and the technical blank of quickly and specifically monitoring the curative effect of plasma exchange is filled; the leap-forward progress of plasma exchange curative effect evaluation from empirical lag judgment to accurate real-time regulation is realized, and the method has remarkable clinical value and commercialization prospect.